Skip to content

Evaluation of the effectiveness, safety, and economy of 68Ga-exendin-4 GLP-1R PET/CT in localizing insulinoma

Evaluation of the effectiveness, safety, and economy of 68Ga-exendin-4 GLP-1R PET/CT in localizing insulinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109212
Enrollment
Unknown
Registered
2025-09-15
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulinoma

Interventions

case group:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 44 Years

Inclusion criteria

Inclusion criteria: 1. Patients with a clear clinical diagnosis of endogenous hyperinsulinermic hypoglycemia and proposed insulinoma 2. Patients should have complete clinical information, including age, gender, treatment costs, hospitalization days, adverse reactions, etc.;

Exclusion criteria

Exclusion criteria: 1. Patients with no confirmed insulinoma 2. Patients without surgery 3. Patient has a previous history of insulinoma (recurrent cases) 4. Incomplete clinical data or quality does not meet the analysis criteria (missing important variables) 5. Patients who have undergone surgery or drug therapy before participating in the study 6. Exclude other diseases that may cause hypoglycemia, such as insulin autoimmune syndrome, islet cell hyperplasia and other hypoglycemia caused by non-insulin causes (adrenal insufficiency, anterior pituitary hypofunction, malnutrition, etc.);

Design outcomes

Primary

MeasureTime frame
adverse reaction;

Countries

China

Contacts

Public ContactLeng Zhiwei

Peking Union Medical College Hospital

lengzhiwei@pumch.cn+86 10 6915 4276

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026